A Phase 2/3, multicenter, randomized, investigator-blinded study to evaluate the efficacy and safety of NK-104 versus Atorvastatin in Chinese patients with hypercholesterolaemia
Phase 2
- Conditions
- hypercholesterolaemia
- Registration Number
- JPRN-jRCT2080220211
- Lead Sponsor
- Kowa Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Main Inclusion Criteria:
Male or female patients diagnosed with hypercholesterolaemia
Main
Exclusion Criteria
Patients with homozygous familial hypercholesterolaemia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method